Nucleic Acid Amplification, Detection, and Diagnostics Market

Report Description

Nucleic Acid Amplification, Detection, and Diagnostics Market Outlook 2032

The global nucleic acid amplification, detection, and diagnostics market size was USD 26.9 Billion in 2023 and is likely to reach USD 81.3 Billion by 2032, expanding at a CAGR of 13.1% during 2024–2032. The market growth is attributed to the ­­increasing awareness of infectious disease and advanced cancer screening.

Nucleic Acid Amplification, Detection, and Diagnostics (NAADD) is a rapidly growing field that utilizes techniques to identify and analyze specific sequences of a patient's DNA or RNA. This information plays a crucial role in diagnosing various diseases, guiding treatment decisions, and monitoring patient progress.

The NAADD market is predicted to reach a substantial size by 2032 due to increasing awareness of infectious diseases and genetic conditions, increasing applications in oncology, personalized medicine, and prenatal testing, and technological advancements resulting in faster, more accessible, and potentially more sensitive tests. The NAADD market is revolutionizing diagnostics by enabling earlier, more accurate diagnoses, improved disease management, personalized healthcare approaches, and enhanced monitoring of infectious diseases. As technology evolves, the market is expected to expand and contribute to better global health outcomes.

The United States Food and Drug Administration (USFDA) regulatory body for nucleic acid amplification tests (NAATs) and related devices, requiring manufacturers to obtain premarket approval through processes like 510(k) clearance or PMA. The FDA also issues guidelines for test validation, labeling, and quality control procedures. In the EU, the EMA is the primary regulatory body for in vitro diagnostics (IVDs), including NAATs, requiring manufacturers to comply with the In Vitro Diagnostic Medical Devices Regulation (IVDR), which outlines requirements for clinical evaluation, performance assessment, and post-market surveillance.

Get Free Sample Report

Impact of Artificial Intelligence (AI) in Nucleic Acid Amplification, Detection, and Diagnostics Market

Artificial intelligence is transforming the NAADD market by making diagnoses sharper. AI analyzes massive datasets from NAADD tests, identifying patterns and variations that might escape human eyes. This translates to earlier, more accurate diagnoses.  Furthermore, AI streamlines workflows by automating data analysis and generating real-time alerts, allowing healthcare professionals to focus on patient care. AI even personalizes treatment decisions by creating patient-specific risk profiles and optimizing treatment protocols based on vast datasets. With AI's help, the NAADD market is poised to deliver not only faster diagnoses, but also more effective and personalized healthcare.

Nucleic Acid Amplification, Detection, and Diagnostics Market Dynamics

Get Free Sample Report

Major Drivers

Increasing awareness of infectious disease and expanding application in advanced cancer diagnostics is expected to boost the market during the forecast period. The rising demand for accurate and early diagnoses across various applications stands out as a major driver in this market. Advancements like Point-of-Care (POC) testing make NAADD more accessible, leading to quicker diagnoses and improved disease management.

Existing Restraints

High costs of NAADD tests, particularly the next generation sequencing is restraining the market. This high-cost limits accessibility especially in low-and middle-income nations. Furthermore, the stringent regulatory framework is delaying the entry of novel NAADD technologies and hence, impeding the market.

Emerging Opportunities

Significant advancements, including point-of-care testing, digital PCR, microfluidics, and lab-on-a-chip technologies are enabling the decentralized testing in remote areas, enhancing diagnostic accuracy and sensitivity. NAADD also plays a key role in companion diagnostics, personalized medicine, and drug dosing. These opportunities is anticipated to improve accessibility, enhance diagnostic accuracy, enable earlier disease detection, personalize treatment plans, and reduce healthcare costs.

Scope of the Nucleic Acid Amplification, Detection, and Diagnostics Market Report

The market report includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Nucleic Acid Amplification, Detection, and Diagnostics Market Segment Insights

Product Type Segment Analysis

Based on product type, the nucleic acid amplification, detection, and diagnostics market is bifurcated into nucleic acid test kits and consumables. The nucleic acid test kits segment is expected to expand at a significant growth rate in 2023 due to higher complexity and value. Nucleic acid test kits involve a combination of reagents, enzymes, and probes specifically designed for targeted amplification and detection. This complexity and higher value compared to individual consumables is fueling the segment. Furthermore, the diversity of applications, including infectious disease testing, oncology testing, genetic testing is boosting the demand of nucleic acid test kits segment. The nucleic acid test kits segment is sub segmented into Polymerase Chain Reaction (PCR) Tests, Real-Time PCR (RT-PCR), Isothermal Nucleic Acid Amplification Technology (INAAT) Tests, and Ligase Chain Reaction (LCR) Tests.

The consumables segment is anticipated to grow at a substantial CAGR during the forecast period due to increasing test volumes. Increasing number of tests is leading to the higher demand for nucleic acid extraction kits, reaction tubes and plates, and enzymes and buffers, driving the segment. Additionally, increase in Point-of-Care (POC) molecular diagnostics, relying on pre-filled cartridges or disposable test kits containing all necessary consumables, is expected to drive the segment. Consumables segment is further sub-segmented into nucleic acid extraction kits, reaction tubes & plates, primers and probes, and enzymes & buffers.

Get Free Sample Report

Application Segment Analysis

On the basis of application, the global market is segregated into infectious disease testing, oncology testing, and genetic & mitochondrial disease testing. The infectious disease testing segment is anticipated to register a considerable CAGR in 2023 due to increasing awareness for infectious diseases among population. The COVID-19 pandemic has played a vital role for boosting the segment. Moreover, the increasing technical advancements and introduction of latest technologies by market players is fueling the segment. For instance,

• In December 2021, Roche, a worldwide healthcare firm with its headquarters in Switzerland has launched its most recent infectious disease tests using the Cobas 5800 System, a cutting-edge molecular laboratory instrument for evaluating molecular nucleic acids in nations that recognize the CE certification.

The oncology testing segment is projected to register a robust growth rate during the assessment years. The increasing number of cancer diagnosis and targeted therapy selection is driving the segment. The oncology testing is used in the detection of cancer mutation and minimal residua disease. Moreover, the increasing awareness for the importance of monitoring treatment response is also boosting the segment.

Technology Segment Analysis

On the basis of technology, the nucleic acid amplification, detection & diagnostics market is segmented into amplification, detection & diagnostics. The detection & diagnostics segment is expected to register a robust growth rate in 2023 due to PCR-based diagnostic tests. These tests detect and quantify the genetic sequence in the sample for specific microbes for disease diagnosis. It is a widely adopted technique in the clinical settings and applications for nucleic acid amplification.

The amplification segment is expected to expand at a significant growth rate over the projection period. These are the foundation, as they enable the exponential increase in target nucleic acid copies, making detection possible. PCR, particularly Real-time PCR, is currently the dominant amplification technology due to its sensitivity, specificity, and real-time results. The increasing demand for NAATs, coupled with advancements in amplification methods, is expected to fuel the segment during the forecast period.

End-user Segment Analysis

Based on end-user, the market is divided into hospitals & clinics, academic & research institutions, diagnostic laboratories, and Point-of-Care (POC) testing. The hospitals & clinics segment is expected to expand at a significant growth rate in 2023. The high volume of diagnostic tests encompassing various applications such as infectious disease identification and cancer screening is boosting the segment. Furthermore, the broad range of skilled specialists is driving the segment. Hospitals and clinics cater to diverse medical specialties, including internal medicine, pediatrics, oncology, and infectious disease. Each specialty utilizes NAATs for various diagnostic purposes, contributing to the high demand within these settings.

The diagnostic laboratories segment is anticipated to grow at a substantial CAGR during the forecast period due to its increasing demand. The diagnostic laboratories are comparatively cheaper and offer specialized test results in lesser time than hospitals. he growing adoption of complex NAATs requiring specialized equipment and trained personnel further fuels the trend of outsourcing to diagnostic laboratories with the necessary infrastructure and expertise.

Get Free Sample Report

Regional Analysis

In terms of region, the global nucleic acid amplification, detection, and diagnostics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market in 2023 owing to developmental activities and pharmaceutical companies in this region. The advancements in the diagnosis of infectious disease and cancer are driving the regional market. Additionally, the frequent collaborations and acquisitions among market players is fueling the regional market significantly. For instance,

• In July 2022, Rite Aid and Quest Diagnostics, a top supplier of diagnostic information services, have announced their partnership. Through the arrangement, Quest PCR testing is expected to be available at Rite Aid's more than 2,350 locations, either through drive-through services or through in-store specimen testing kits.

The market in Asia Pacific is projected to grow at a significant pace in the years to come owing to increasing rate of infectious diseases. Moreover, the increasing government support and investments is expected to fuel the regional market. Many governments in the Asia Pacific region are prioritizing investments in healthcare infrastructure and development. According to World Economic Forum, Asia-Pacific is home to about 60% of the world’s population. The large size of population surges the demand for rapid and quality detection of infectious and non-infectious diseases, driving the regional segment.

Get Free Sample Report